Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
Authors
Keywords
-
Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 79, Issue 17, Pages 1660-1671
Publisher
Elsevier BV
Online
2022-04-26
DOI
10.1016/j.jacc.2022.02.035
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk
- (2021) Brian Olshansky et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation
- (2021) Christine M. Albert et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides
- (2021) Manan Pareek et al. Expert Opinion On Drug Safety
- Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
- (2021) John W. Eikelboom et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia
- (2021) Salim S. Virani et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization
- (2021) Ram D. Bhatt et al. PROGRESS IN CARDIOVASCULAR DISEASES
- A randomized trial of icosapent ethyl in ambulatory patients with COVID-19
- (2021) Andrew Kosmopoulos et al. iScience
- Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG
- (2021) Subodh Verma et al. CIRCULATION
- Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
- (2021) Arjun Majithia et al. CIRCULATION
- Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
- (2021) Prakriti Gaba et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability
- (2021) Samuel C.R. Sherratt et al. PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
- Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
- (2020) R. Preston Mason et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association
- (2020) Suzanne V. Arnold et al. CIRCULATION
- Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: A prospective, placebo-controlled randomized trial (EVAPORATE): Interim Results
- (2020) Matthew J Budoff et al. CARDIOVASCULAR RESEARCH
- Applicability of the REDUCE‐IT trial to the FAST‐MI registry. Are the results of randomized trials relevant in routine clinical practice?
- (2020) Jean Ferrières et al. CLINICAL CARDIOLOGY
- Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction
- (2020) Suzanne V. Arnold et al. JAMA Network Open
- The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
- (2020) Xiaowen Wang et al. Current Diabetes Reports
- Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
- (2020) Matthew J Budoff et al. EUROPEAN HEART JOURNAL
- Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside
- (2020) Deepak L Bhatt EUROPEAN HEART JOURNAL SUPPLEMENTS
- REDUCE-IT INTERIM: Accumulation of Data Across Prespecified Interim Analyses to Final Results
- (2020) Brian Olshansky et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Reduction in Revascularization With Icosapent Ethyl
- (2020) Benjamin E. Peterson et al. CIRCULATION
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk
- (2020) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
- (2019) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- REDUCE-IT
- (2019) Deepak L Bhatt EUROPEAN HEART JOURNAL
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes
- (2019) Philippe Gabriel Steg et al. CIRCULATION
- Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles
- (2019) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- REDUCE-IT USA: Results from the 3,146 Patients Randomized in the United States
- (2019) Deepak L. Bhatt et al. CIRCULATION
- Reply
- (2019) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
- (2019) William E Boden et al. EUROPEAN HEART JOURNAL
- Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
- (2018) Om P. Ganda et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
- (2017) John W. Eikelboom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries
- (2017) Lisandro D. Colantonio et al. JAMA Cardiology
- Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes
- (2016) R. Preston Mason et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
- (2015) Marc P. Bonaca et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis
- (2010) Deepak L. Bhatt et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started